Compile Data Set for Download or QSAR
Report error Found 7 Enz. Inhib. hit(s) with all data for entry = 12734
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Astrazeneca

US Patent
LigandPNGBDBM349662(2-{[4-(6-{[(4-cyano-2-fluorophenyl)(methyl-d2)]oxy...)
Affinity DataIC50: 2.00E+3nMAssay Description:Evaluation of the effects of compounds on the activity of the human phosphodiesterase-3A is quantified by measuring the formation of 5′AMP from cAMP ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2025
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Astrazeneca

US Patent
LigandPNGBDBM724207(WO2020103815, Ex 19 | WO2020103815, Compound 19 | ...)
Affinity DataIC50: 4.00E+3nMAssay Description:Evaluation of the effects of compounds on the activity of the human phosphodiesterase-3A is quantified by measuring the formation of 5′AMP from cAMP ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/30/2025
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Astrazeneca

US Patent
LigandPNGBDBM603919(US11655242, Example 2 | 2-[[4-[6-[(4-Cyano-2-fluor...)
Affinity DataIC50: 5.00E+3nMAssay Description:Evaluation of the effects of compounds on the activity of the human phosphodiesterase-3A is quantified by measuring the formation of 5′AMP from cAMP ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2025
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Astrazeneca

US Patent
LigandPNGBDBM724208(WO2018109607, Ex 4A-01 | US20250066338, Ref Comp B)
Affinity DataIC50: 1.10E+4nMAssay Description:Evaluation of the effects of compounds on the activity of the human phosphodiesterase-3A is quantified by measuring the formation of 5′AMP from cAMP ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/30/2025
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Astrazeneca

US Patent
LigandPNGBDBM724204(2-(((1R,5S,6S)-6-(6-((4-Chloro-2-fluorobenzyl)oxy)...)
Affinity DataIC50: 1.00E+5nMAssay Description:Evaluation of the effects of compounds on the activity of the human phosphodiesterase-3A is quantified by measuring the formation of 5′AMP from cAMP ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/30/2025
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Astrazeneca

US Patent
LigandPNGBDBM724205(2-(((1R,5S,6r)-6-(6-((4-Chloro-2-fluorobenzyl)oxy)...)
Affinity DataIC50: 1.00E+5nMAssay Description:Evaluation of the effects of compounds on the activity of the human phosphodiesterase-3A is quantified by measuring the formation of 5′AMP from cAMP ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/30/2025
Entry Details
Go to US Patent

TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A(Human)
Astrazeneca

US Patent
LigandPNGBDBM724206(2-(((1R,5S,6S)-6-(6-((4-Chloro-2-fluorobenzyl)oxy)...)
Affinity DataIC50: 1.00E+5nMAssay Description:Evaluation of the effects of compounds on the activity of the human phosphodiesterase-3A is quantified by measuring the formation of 5′AMP from cAMP ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/30/2025
Entry Details
Go to US Patent